Singh Kanwar Samrat, Chandola Harimohan, Kaur Mandip, Ravishankar B
Lecturer, Department of Kaya Chikitsa, SKSS Ayurvedic College, Sarabha, Ludhiana, Punjab, India.
Ayu. 2012 Jul;33(3):368-73. doi: 10.4103/0974-8520.108825.
Type-2 diabetes mellitus is a persistent health problem that requires innovative strategies to improve health and needs a multifactorial approach for the treatment. Saptarangyadi Ghanavati, a new formulated Ayurvedic compound consists of herbs with anti-diabetic potential, in addition to a folklore herb Saptarangi (Salacia chinensis) has been evaluated. In a total of 67 patients, 36 patients were of newly detected type-2 diabetes mellitus and 31 patients were of chronic type-2 diabetes mellitus and they were divided into group A and group B, respectively. Group A consisted newly detected subjects of type-2 diabetes and were not taking any regular medication and group B consisted of chronic cases of type-2 diabetes mellitus, who were taking modern ant-diabetic medication, but their blood-glucose level was not controlled to desired level. Patients in group A were administered Saptarangyadi Ghanavati each of 200 mg, 5 Vatis, 3-times a day-after breakfast, lunch, and dinner. Patients in group B were administered Saptarangyadi Ghanavati, in the same dose in addition to the concomitant anti-diabetic (Allopathic) medication. Serum insulin investigation, both fasting and post-prandial levels were evaluated in six patients of group B, showed a highly significant increase in first-phase insulin response. Glycosylated hemoglobin (serum HbA1c) evaluated in six patients of group A showed statistically significant reduction. There was also statistically significant reduction in the fasting blood sugar (FBS) and post prandial blood sugar (PPBS) parameters, both in newly detected cases as well as chronic cases of type-2 diabetes mellitus.
2型糖尿病是一个持续存在的健康问题，需要创新策略来改善健康状况，且治疗需要采取多因素方法。已对一种新配制的阿育吠陀化合物Saptarangyadi Ghanavati进行了评估，该化合物除了一种民间草药七叶藤（中华五层龙）外，还含有具有抗糖尿病潜力的草药。总共67例患者中，36例为新诊断的2型糖尿病患者，31例为慢性2型糖尿病患者，他们分别被分为A组和B组。A组由新诊断的2型糖尿病患者组成，未服用任何常规药物，B组由慢性2型糖尿病患者组成，他们正在服用现代抗糖尿病药物，但其血糖水平未控制到理想水平。A组患者每天服用200毫克Saptarangyadi Ghanavati，即5丸，一日三次，分别在早餐、午餐和晚餐后服用。B组患者除了服用伴随的抗糖尿病（西医）药物外，还服用相同剂量的Saptarangyadi Ghanavati。对B组的6例患者进行了空腹和餐后血清胰岛素水平检测，结果显示第一阶段胰岛素反应有极显著增加。对A组的6例患者进行糖化血红蛋白（血清HbA1c）检测，结果显示有统计学意义的降低。无论是新诊断的2型糖尿病病例还是慢性2型糖尿病病例，空腹血糖（FBS）和餐后血糖（PPBS）参数也都有统计学意义的降低。
